SYHA 1813
Alternative Names: SYHA-1813Latest Information Update: 24 Dec 2024
At a glance
- Originator Shanghai Institute of Materia Medica
- Developer Shanghai Runshi Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Macrophage colony-stimulating factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glioblastoma; Solid tumours
Most Recent Events
- 18 Dec 2024 Shanghai Runshi Pharmaceutical Technology plans a phase II trial for Meningioma (Recurrent) in January 2025 (NCT06739213)
- 11 Nov 2024 Shanghai Runshi Pharmaceutical Technology plans phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherpy and Combination therapy) (PO) (NCT06682611)
- 13 Sep 2024 SYHA 1813 is still in phase I trials for Solid tumours in China